Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose dose-escalation study of NNC126-0083 versus Norditropin NordiFlex in children with growth hormone deficiency
2008-008240-25Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in growth hormone deficiency (GHD) comparing NNC126-0083 dose-escalation with Norditropin NordiFlex (2 arms). Primary endpoint: Adverse events. Started Apr 2009; status: completed.
02
Drugs
somatropin pegolNorditropine SimpleXxsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2008-008240-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008240-25.